Researchers from South Korea said they have developed a next-generation sequencing (NGS) assay to detect somatic mutations, translocations, and germline mutations in a single assay for the purpose of supplementing or replacing conventional tests in patients with myeloid neoplasms.
Researchers from South Korea said they have developed a next-generation sequencing (NGS) assay to detect somatic mutations, translocations, and germline mutations in a single assay for the purpose of supplementing or replacing conventional tests in patients with myeloid neoplasms.
Writing in a recent issue of PLoS One, the researchers said were able to discover a high frequency of germline mutations in cancer predisposition genes. Patients with these mutations exhibited different clinical characteristics, suggesting that germline predisposition has significant clinical implications.
Other whole genome and exome studies have revealed a wide genetic heterogeneity in myeloid neoplasm by discovering oncogenic mutations in hundreds of genes, the authors explained.
They noted that the 2016 World Health Organization revised classification of myeloid neoplasms and acute leukemia introduced a number of genes with somatic mutations and a category for germline predisposition syndromes in myeloid neoplasms for use in classifying cases with an inherited defect.
Compared with conventional tests, NGS testing can identify a number of mutations that are critical for diagnosis and risk stratification in a relatively short time. Conventional testing methods, such as fluorescence in situ hybridization and reverse transcription polymerase chain reaction, can be used to detect various type of genetic variations, including structural variations.
The NGS assay developed by the researchers covers genes for most germline predisposition syndromes and intronic hotpots of 12 recurrently translocated genes. They conducted extensive bioinformatics analyses, such as by recycling off-target data to analyze whole-genome copy number status, which could supplement conventional cytogenetics.
The researchers analyzed bone marrow aspirates of patients diagnosed with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm between July 2016 and May 2017. They found that 8.4% to 11.6% of patients with acute myeloid leukemia and 12.9% of patients with myeloproliferative neoplasms had germline mutations, and most were heterozygous carriers for autosomal recessive marrow failure syndromes. These patients often did not respond to standard chemotherapy, suggesting that germline predisposition may have distinct and significant clinical implications.
Reference
KimB, Lee H, Jang J, et al. Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms [published online March 6, 2019]. PLoS One. doi: 10.1371/journal.pone.0212228.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More